In summary, our analysis of the prognostic role of KRAS-mutations in a study cohort with newly diagnosed MM, uniformly treated with three cycles of VCD and subsequent stem cell mobilization, high-dose chemotherapy, and autologous stem cell transplantation, did not reveal a significant correlation with survival. This evidence concerns the gene KRAS and Miyoshi myopathy.